|
Mar 25
|
Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial
|
|
Mar 20
|
Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024
|
|
Jan 16
|
What Makes Syros Pharmaceuticals, Inc. (SYRS) a New Buy Stock
|
|
Jan 16
|
Wall Street Analysts Predict a 199.31% Upside in Syros Pharmaceuticals, Inc. (SYRS): Here's What You Should Know
|
|
Jan 11
|
Why Syros Pharmaceuticals (SYRS) Stock Might be a Great Pick
|
|
Dec 19
|
Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants
|
|
Dec 7
|
Syros (SYRS) Rises on Upbeat Initial Study Data on Tamibarotene
|
|
Dec 6
|
Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine
|
|
Nov 7
|
Syros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023
|